NCT05001269View on ClinicalTrials.gov

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2Primary Hyperoxaluria Type 3
Interventions
DRUG

nedosiran

Monthly subcutaneous dosing throughout study period

Trial Locations (13)

1100

Clinical Research Site, Beirut

53127

Clinical Trial Site, Bonn

55905

Clinical Research Site, Rochester

69120

Clinical Research Site, Heidelberg

L8S 4K1

Clinical Research Site, Hamilton

00165

Clinical Trial Site, Roma

830-0011

Clinical Research Site, Fukuoka

467-8602

Clinical Research Site, Nagoya

15-274

Clinical Research Site, Bialystok

08035

Clinical Research Site, Barcelona

06506

Clinical Research Site, Yenimahalle

+971

Clinical Trial Site, Dubai

WC1N 3JH

Clinical Trial Site, London

All Listed Sponsors
lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY